Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lavipharm S.A. is a healthcare company specializing in the development and manufacturing of generic and specialty pharmaceuticals, primarily targeting markets in Europe and the Mediterranean region. Its competitive position is bolstered by a diverse product portfolio and a robust pipeline of generic drugs, which are critical in driving revenue growth amidst increasing market demand for affordable medications.
Lavipharm generates revenue through the sale of generic and specialty pharmaceuticals, leveraging its established relationships with healthcare providers and distributors. The company's competitive advantages include a strong R&D capability, a well-optimized supply chain, and regulatory expertise that enables faster product approvals.
Approval of new generic drugs in key markets such as the EU and Mediterranean
Changes in healthcare regulations affecting pricing and reimbursement
Market share gains against competitors in the generic segment
Fluctuations in raw material costs impacting margins
Regulatory changes that could impact drug pricing and market access
Technological disruptions in drug development processes
Intensifying competition from other generic drug manufacturers
Potential entry of large pharmaceutical companies into the generic market
Moderate debt levels could limit financial flexibility in downturns
Liquidity concerns due to low free cash flow generation
moderate - The company's performance is somewhat linked to GDP growth, as healthcare spending tends to rise in stronger economic conditions.
Rising interest rates could increase financing costs for Lavipharm, potentially impacting its ability to invest in R&D and expansion, thus affecting valuation multiples.
minimal - The company maintains a manageable debt-to-equity ratio of 0.50, indicating limited reliance on external credit.
growth - Investors are likely attracted to Lavipharm due to its strong revenue growth potential from new product launches.
moderate - The stock has shown significant price movements, with a historical beta indicating moderate volatility.